Searched for: in-biosketch:true
person:bangas01
Inotropic contractile reserve and response to cardiac resynchronization therapy in patients with markedly remodeled left ventricle
Chaudhry, Farooq A; Shah, Ajay; Bangalore, Sripal; DeRose, Joseph; Steinberg, Jonathan S
BACKGROUND: Recently concluded multicenter studies have shown that none of an array of echocardiographic indicators of ventricular dyssynchrony have enough sensitivity and specificity for predicting response to cardiac resynchronization therapy (CRT). Inotropic contractile reserve (ICR) on dobutamine stress echocardiography can differentiate viable myocardium from scar and is a predictor of improvement in regional and global left ventricular function in patients with cardiomyopathy. Its role in patients undergoing CRT is unknown. The aim of this study was to evaluate the role of ICR in predicting response to CRT in patients with markedly remodeled left ventricles. METHODS: Fifty-four patients (mean age, 69+/-11 years; 63% men) referred for clinically indicated CRT were evaluated. All patients underwent low-dose dobutamine stress echocardiography to assess for ICR, defined as an improvement in contractility in more than five of 16 left ventricular segments. RESULTS: During a mean follow-up period of 206+/-167 days, 31 patients (57%) were responders, as defined by a 5-point increase in ejection fraction after CRT. The presence of ICR was a stronger predictor of response to CRT (area under the curve, 0.94; chi2=39.0; P<.0001) compared with dyssynchrony (area under the curve, 0.74; chi2=10.07; P=.002). It was a significant predictor of response (odds ratio, 2.84; 95% confidence interval, 1.59 to 5.09; P<.0001), even after controlling for the other predictors, and provided incremental prognostic value beyond that provided by QRS duration and dyssynchrony (increase in area under the curve from 0.47 to 0.75 to 0.93; P=.030 and P=.008). CONCLUSIONS: In patients referred for CRT, ICR was a stronger predictor of response and provided incremental value beyond that of current known predictors of response to CRT (dyssynchrony and QRS duration). Dobutamine stress echocardiography may have an important role in identifying CRT responders, and further multicenter studies are needed to confirm this
PMID: 21126856
ISSN: 1097-6795
CID: 133201
Treating symptomatic carotid artery disease: Deciding between carotid artery stenting and carotid endarterectomy - Balancing the risks
Bangalore S.
EMBASE:2011145129
ISSN: 1755-5302
CID: 129333
Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure
Ather, Sameer; Bangalore, Sripal; Vemuri, Srinath; Cao, Long B; Bozkurt, Biykem; Messerli, Franz H
Cardiac resynchronization therapy (CRT) increases cardiac performance in patients with heart failure, but its effect on arterial pressure is not well established. To determine the effect of CRT on systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) a systematic review using standard nomenclatures for CRT was done in Scopus (MEDLINE and Embase), Cochrane Controlled Trials Register, National Institutes of Health http://www.ClinicalTrials.gov database, and bibliography of select meta-analyses for studies evaluating CRT in patients with dilated cardiomyopathy. Two independent investigators extracted the articles based on predefined criteria. The primary outcome was difference in arterial pressure parameters from baseline to after CRT in nonrandomized cohort trials. This was then validated by comparing the change in arterial pressure between CRT and medical therapy groups in randomized controlled trials. A random-effects model was used for analyses. Analyses of 15 nonrandomized studies showed that CRT resulted in an increase (from baseline) in SBP by 4.4 mm Hg (95% confidence interval [CI] 0.8 to 8.0, p = 0.02), no change in DBP (p = 0.21), and an increase in PP by 2.8 mm Hg (95% CI 1.0 to 4.6, p = 0.003). Results from the 3 randomized controlled trials were concordant with an increase in SBP by 3.9 mm Hg (95% CI 1.1 to 6.8, p = 0.007), no effect on DBP (p = 0.40), and an increase in PP by 4.3 mm Hg (95% CI 4.1 to 4.5, p <0.001) compared to medical therapy. In conclusion, CRT is associated with a modest increase in SBP and PP in patients with heart failure
PMID: 21184988
ISSN: 1879-1913
CID: 150585
Blood pressure and stroke: findings from recent trials [Letter]
Messerli, Franz H; Bangalore, Sripal
PMID: 21185511
ISSN: 1558-3597
CID: 150584
Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography
Wever Pinzon, Omar; Silva Enciso, Jorge; Romero, Jorge; Makani, Harikrishna; Fefer, Jose; Gandhi, Vani; Bangalore, Sripal; Chaudhry, Farooq A
BACKGROUND: Patients with human immunodeficiency virus (HIV) infection are at increased risk of accelerated coronary artery disease (CAD) and cardiovascular events. Stress echocardiography (SE) is routinely used for risk stratification and prognosis of patients with known or suspected CAD. The prognostic value of SE in this high-risk group is unknown. The purpose of this study was to evaluate the prognostic value of SE in HIV-infected patients with known or suspected CAD. METHODS AND RESULTS: We evaluated 311 patients (age, 52 +/- 9 years; 74% men; left ventricular ejection fraction, 54 +/- 12%) with history of HIV, undergoing SE (56% dobutamine). Left ventricular wall motion was evaluated on a 16-segment model, 5-point scale. An abnormal SE was defined by a fixed (infarction), biphasic, or new (ischemia) wall motion abnormality on stress. Follow-up for cardiac death and myocardial infarction was obtained. Seventy-nine (26%) patients had an abnormal SE. After 2.9 +/- 1.9 years, 17 confirmed myocardial infarction and 14 cardiac deaths occurred. SE risk-stratified patients into normal versus abnormal subgroups (event rate, 0.6% per year versus 11.8% per year; P < 0.0001). Both abnormal SE (hazard ratio, 28.2; 95% confidence interval, 6.2 to 128.0; P < 0.0001) and the presence of any ischemia on SE (hazard ratio, 3.4; 95% confidence interval, 1.3 to 8.6; P = 0.009) were independent predictors of cardiac events. On a forward conditional Cox proportional hazards regression model, SE provided incremental prognostic value over clinical, stress ECG, and resting echocardiographic variables (global chi(2) increased from 17.8 to 24.5 to 65 to 109, P < 0.05 across all groups). CONCLUSIONS: SE can effectively risk-stratify and prognosticate patients with HIV. The presence of ischemia and scar during SE provides independent and incremental prognostic value over traditional variables. A normal SE response portends a benign prognosis even in this high-risk subset
PMCID:3593109
PMID: 21750273
ISSN: 1942-0080
CID: 150583
Half a century of hydrochlorothiazide: facts, fads, fiction, and follies
Messerli, Franz H; Bangalore, Sripal
Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US. In 2008, 47.8 million prescriptions were written for HCTZ alone and 87.1 million prescriptions for HCTZ combinations. However, there is no evidence that HCTZ in its usual dose of 12.5-25 mg daily reduces myocardial infarction, stroke, or death. In a meta-analysis of 19 randomized trials with over 1400 patients, the 24-hour decrease in blood pressure with HCTZ was inferior to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and calcium channel blockers (P <.001 for all). Even in combination with an angiotensin-converting enzyme inhibitor, HCTZ was found to reduce morbidity and mortality less well than a calcium channel blocker. As measured by the adherence rate, thiazides are less well tolerated than any other drug class. Because outcome data at the usual daily dose of 12.5-25 mg are lacking, antihypertensive efficacy is paltry, and adherence is poor, HCTZ is an inappropriate first-line drug in hypertension. If a 'thiazide-type' diuretic is indicated, either chlorthalidone or indapamide should be selected
PMID: 21962309
ISSN: 1555-7162
CID: 150582
Inotropic contractile reserve can risk-stratify patients with HIV cardiomyopathy: a dobutamine stress echocardiography study
Wever-Pinzon, Omar; Bangalore, Sripal; Romero, Jorge; Silva Enciso, Jorge; Chaudhry, Farooq A
OBJECTIVES: The purpose of this study was to assess whether inotropic contractile reserve (ICR) during dobutamine stress echocardiography (DSE) could risk-stratify patients with human immunodeficiency virus (HIV) cardiomyopathy and predict improvement of left ventricular ejection fraction (LVEF). BACKGROUND: HIV cardiomyopathy is an important cause of heart failure and death. ICR is associated with better survival and improvement of LVEF in patients with ischemic and nonischemic cardiomyopathies. However, the prognostic value of ICR in patients with HIV cardiomyopathy is unknown. METHODS: Patients with HIV cardiomyopathy and a LVEF <45% who were referred for DSE were enrolled. ICR was evaluated by the delta wall motion score index (DeltaWMSI), calculated as the difference between rest and peak WMSI. Patients were followed for cardiac death and change in LVEF on follow-up. RESULTS: Sixty patients (75% men; age, 54 +/- 9 years) with HIV cardiomyopathy (mean LVEF, 28 +/- 11%) formed the study group. After 2.4 +/- 2.1 years, 11 cardiac deaths occurred (event rate of 7.6%/year). A receiver-operating characteristic curve identified a DeltaWMSI of 0.38 as an optimal cut point for the presence of ICR, with a specificity of 88% and a sensitivity of 73% for the prediction of cardiac death. On univariable analysis, the absence of ICR (hazard ratio: 6.6; 95% confidence interval: 1.93 to 22.62; p = 0.003) and New York Heart Association functional class IV (hazard ratio: 7.2; 95% confidence interval: 2.20 to 23.65; p = 0.001) were the only predictors of cardiac death. After 2.1 +/- 1.8 years, 41 patients had a follow-up echocardiogram. LVEF improvement from baseline occurred in 23 patients (56%), more so in patients with ICR than without ICR. A DeltaWMSI of 0.59 predicted improvement in the LVEF with a specificity of 78% and a sensitivity of 74%. CONCLUSIONS: The presence of ICR during DSE can risk-stratify and predict subsequent improvement in LVEF in patients with HIV cardiomyopathy
PMCID:3595113
PMID: 22172778
ISSN: 1876-7591
CID: 150580
Meta-Analysis of Multivessel Coronary Artery Revascularization Versus Culprit-Only Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease
Bangalore, Sripal; Kumar, Sunil; Poddar, Kanhaiya L; Ramasamy, Sureshkumar; Rha, Seung-Woon; Faxon, David P
American College of Cardiology/American Heart Association guidelines for management of patients with ST-segment elevation myocardial infarction (STEMI) recommend culprit artery-only revascularization (CULPRIT) based on safety concerns during noninfarct-related artery intervention. However, the data to support this safety concern are scant. Searches were performed in PubMed/EMBASE/CENTRAL for studies evaluating multivessel revascularization versus CULPRIT in patients with STEMI and multivessel disease (MVD). A multivessel revascularization strategy had to be performed at the time of CULPRIT or during the same hospitalization. Early (</=30-day) and long-term outcomes were evaluated. Among 19 studies (23 arms) that evaluated 61,764 subjects with STEMI and MVD, multivessel revascularization was performed in a minority of patients (16%). For early outcomes, there was no significant difference for outcomes of mortality, MI, stroke, and target vessel revascularization, with a 44% decrease in risk of repeat percutaneous coronary intervention and major adverse cardiovascular events (odds ratio 0.68, 95% confidence interval 0.57 to 0.81) with multivessel revascularization compared to CULPRIT. Similarly, for long-term outcomes (follow-up 2.0 +/- 1.1 years), there was no difference for outcomes of MI, target vessel revascularization, and stent thrombosis, with 33%, 43%, and 53% decreases in risk of mortality, repeat percutaneous coronary intervention, coronary artery bypass grafting, respectively, and major adverse cardiovascular events (odds ratio 0.60, 95% confidence interval 0.50 to 0.72) with multivessel revascularization compared to CULPRIT. In conclusion, in patients with STEMI and MVD, multivessel revascularization appears to be safe compared to culprit artery-only revascularization. These findings support the need for a large-scale randomized trial to evaluate revascularization strategies in patients with STEMI and MVD
PMID: 21349487
ISSN: 1879-1913
CID: 131594
Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials
Bangalore, Sripal; Kumar, Sunil; Wetterslev, Jorn; Messerli, Franz H
OBJECTIVES: To evaluate the cardiovascular outcomes and other outcomes associated with angiotensin receptor blockers. DESIGN: Systematic review of randomised controlled trials with meta-analysis and trial sequential analysis (TSA). Data sources and study selection Pubmed, Embase, and CENTRAL searches for randomised clinical trials, until August 2010, of angiotensin receptor blockers compared with controls (placebo/active treatment) that enrolled at least 100 participants and had a follow-up of at least one year. DATA EXTRACTION: Myocardial infarction, death, cardiovascular death, angina pectoris, stroke, heart failure, and new onset diabetes. RESULTS: 37 randomised clinical trials included 147 020 participants and had a total follow-up of 485 166 patient years. When compared with controls (placebo/active treatment), placebo, or active treatment, angiotensin receptor blockers were not associated with an increase in the risk of myocardial infarction (relative risk 0.99, 95% confidence interval 0.92 to 1.07), death, cardiovascular death, or angina pectoris. Compared with controls, angiotensin receptor blockers were associated with a reduction in the risk of stroke (0.90, 0.84 to 0.98), heart failure (0.87, 0.81 to 0.93), and new onset diabetes (0.85, 0.78 to 0.93), with similar results when compared with placebo or with active treatment. Based on trial sequential analysis, there is no evidence even for an average 5.0-7.5% (upper confidence interval 5-11%) relative increase in myocardial infarction (absolute increase of 0.3%), death, or cardiovascular death with firm evidence for relative risk reduction of stroke (at least 1%, average 10%) (compared with placebo only), heart failure (at least 5%, average 10%), and new onset diabetes (at least 4%, average 10%) with angiotensin receptor blockers compared with controls. CONCLUSIONS: This large and comprehensive analysis produced firm evidence to refute the hypothesis that angiotensin receptor blockers increase the risk of myocardial infarction (ruling out even a 0.3% absolute increase). Compared with controls, angiotensin receptor blockers reduce the risk of stroke, heart failure, and new onset diabetes
PMCID:3082637
PMID: 21521728
ISSN: 0959-8146
CID: 131824
Methodological Remarks Concerning the Recent Meta-analysis of Carotid Artery Stenting vs Carotid Endarterectomy reply [Letter]
Bangalore, Sripal; Bhatt, Deepak L.
ISI:000289368800029
ISSN: 0003-9942
CID: 131843